Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial

Purpose: The aim of this phase Ib study (clinicaltrials.gov: NCT01772732) was to assess safety, tolerability, and pharmacokinetics (PKs) of simotinib (a novel EGFR tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer (NSCLC) and EGFR gene mutation. Patients and methods: 41...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xing-Sheng, Han, Xiao-Hong, Yang, Sheng, Li, Ning, Wang, Lin, Song, Yuan-Yuan, Mu, Hua, Shi, Yuan-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525002/
https://www.ncbi.nlm.nih.gov/pubmed/31191007
http://dx.doi.org/10.2147/CMAR.S189626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525002/
https://www.ncbi.nlm.nih.gov/pubmed/31191007
http://dx.doi.org/10.2147/CMAR.S189626

Ejemplares similares